Closing remarks: current status of labetalol.
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D000818:Animals; D000959:Antihypertensive Agents; D004983:Ethanolamines / Q000494:pharmacology; D005123:Eye / Q000187:drug effects; D006801:Humans; D007024:Hypotension, Orthostatic / Q000139:chemically induced; D007741:Labetalol / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D004983:Ethanolamines; D007741:Labetalol